Diabetes-Drug Makers Face FDA Hurdle
Concern over reports that link diabetes drugs to heart trouble is compelling U.S. drug regulators to ask diabetes-drug makers for more safety data. These requests for additional data could delay new product approvals by years and add millions of dollars to development and post-market commitment costs.
The U.S. Food and Drug Administration is reportedly sending letters to all companies with diabetes drugs in development, informing them that the agency will now require safety data prior to approval that measures a drug's cardiovascular risk.
Companies reportedly receiving the FDA letters include Amylin Pharmaceuticals (AMLN), Vivus (VVUS), Incyte Pharmaceuticals (INCY) and Roche, according to sources familiar with the letters. All have diabetes drugs in mid- to late-stage clinical trials.
"It appears companies with drugs at the FDA -- Novo Nordisk (NVO)(liraglutide), Takeda (alogliptin) and AstraZeneca (AZN)/ Bristol-Myers Squibb (BMY) (saxagliptin) -- have not yet received a letter, although discussions with industry participants lead us to believe they are coming," wrote Morgan Stanley biotech analyst Steve Harr in a note to clients on Friday. "The companies under review have the greatest uncertainty, and outcomes will impact these companies and competitors."Novo Nordisk's drug, liraglutide, is expected to be discussed at an upcoming advisory panel meeting. An FDA spokesperson would not comment on the letters, stating only that the agency is working on guidance on issues surrounding cardiovascular risk and diabetes drugs. Research published in 2007 linked Avandia, a diabetes drug marketed by GlaxoSmithKline (GSK), to an increased risk of heart attack in people with type 2 diabetes. Since then, the cardiovascular risk of all diabetes drugs has become a major concern for regulators both in Europe and the U.S.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV